home All News open_in_new Full Article

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for […]


today 2 w. ago attach_file Other

attach_file Events
attach_file Other
attach_file Society
attach_file Other
attach_file Culture
attach_file Society


ID: 2347041126
Add Watch Country

arrow_drop_down